Video

Laura Metcalfe on the Virtual Colonoscopy

Author(s):

Laura Metcalfe, MSN, RN

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on the Virtual Colonoscopy

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on the Virtual Colonoscopy

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Related Content
FDA
October 9th 2024

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Ruihua Xu, MD, PhD, of Sun Yat-sen University Cancer Center
September 25th 2024

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.
September 24th 2024

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer